COGNITIVE AND BEHAVIORAL EFFECTS OF LONG TERM ANTIEPILEPTIC DRUG USE IN ADOLESCENTS WITH GENERALIZED EPILEPSY
DOI:
https://doi.org/10.71000/nxjqa547Keywords:
Generalized Epilepsy, Antiepileptic Drugs, Adolescents, Cognitive Impairment, Behavioral Effects, Narrative ReviewAbstract
Background: Adolescents with generalized epilepsy often require long-term antiepileptic drug (AED) therapy during a critical phase of cognitive and emotional development. While AEDs are essential for seizure control, increasing evidence suggests they may adversely affect cognition and behavior, raising concerns about their broader impact on quality of life and neurodevelopment.
Objective: This narrative review aims to explore and synthesize current evidence on the cognitive and behavioral consequences of prolonged AED use in adolescents with generalized epilepsy, highlighting differences among commonly prescribed medications and identifying areas in need of further investigation.
Main Discussion Points: The review discusses cognitive impairments associated with older AEDs such as valproate and carbamazepine, which are more pronounced compared to newer agents like levetiracetam and oxcarbazepine. Behavioral issues, including emotional instability and attention deficits, are also prevalent. Themes such as treatment duration, monotherapy versus polytherapy, variability in neuropsychological assessments, and methodological gaps in the literature are critically analyzed. Emerging therapies and the need for routine cognitive monitoring are highlighted.
Conclusion: The existing literature supports a cautious, individualized approach to AED therapy in adolescents, with attention to neurocognitive outcomes alongside seizure control. Further pediatric-focused, long-term research is essential to guide safer clinical practices and informed policy development.
References
Shakeshaft A, Panjwani N, McDowall R, Crudgington H, Peña Ceballos J, Andrade DM, et al. Trait impulsivity in Juvenile Myoclonic Epilepsy. Ann Clin Transl Neurol. 2021;8(1):138-52.
Fayad C, Saad K, Kahwagi GJ, Hallit S, Griffin D, Abou-Khalil R, et al. A systematic review and meta-analysis of factors related to first line drugs refractoriness in patients with juvenile myoclonic epilepsy (JME). PLoS One. 2024;19(4):e0300930.
Shaikh BA, Gurbakhshani KM, Muhammad SK. Frequency of atrial fibrillation in patients of ischemic stroke. SZMC. 2017;31:120-6.
Cerulli Irelli E, Cocchi E, Gesche J, Peña-Ceballos J, Caraballo RH, Lattanzi S, et al. Second-Line Medications for Women Aged 10 to 50 Years With Idiopathic Generalized Epilepsy. JAMA Netw Open. 2025;8(3):e250354.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375-86.
Gidal B, Detyniecki K. Rescue therapies for seizure clusters: Pharmacology and target of treatments. Epilepsia. 2022;63 Suppl 1(Suppl 1):S34-s44.
Komatsubara T, Kobayashi Y, Hiraiwa A, Magara S, Hojo M, Ono T, et al. Recurrence rates and risk factors for seizure recurrence following antiseizure medication withdrawal in adolescent patients with genetic generalized epilepsy. Epilepsia Open. 2022;7(2):332-43.
Striano P, Auvin S, Collins A, Horvath R, Scheffer IE, Tzadok M, et al. A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome. Epilepsia. 2022;63(7):1748-60.
Foster E, Chen Z, Vaughan DN, Tailby C, Carney PW, D'Souza W, et al. Prospective multisite cohort study of patient-reported outcomes in adults with new-onset seizures. Epilepsia Open. 2022;7(1):201-9.
Wirrell EC, Lagae L, Scheffer IE, Cross JH, Specchio N, Strzelczyk A. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. Epilepsia Open. 2024;9(5):1643-57.
Delanty N, Mohanraj R, Shankar R, Wehner T, Stephen LJ, D'Souza W, et al. Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study. Epilepsy Res. 2024;202:107339.
Devinsky O, Marmanillo A, Hamlin T, Wilken P, Ryan D, Anderson C, et al. Observational study of medical marijuana as a treatment for treatment-resistant epilepsies. Ann Clin Transl Neurol. 2022;9(4):497-505.
Villanueva V, Carreño-Martínez M, Gil Nagel-Rein A, López-González FJ. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol. Rev Neurol. 2021;72(S01):S1-s10.
Vossler DG, Farkas MK, Poverennova I, Watanabe M, Conrath P, Dimova S, et al. Long-term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic-clonic seizures: An open-label extension trial. Epilepsia. 2024;65(12):3488-500.
Scheffer IE, Nabbout R, Lagae L, Devinsky O, Auvin S, Thiele EA, et al. Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia. 2025;66(6):1919-32.
Zeka N, Zogaj L, Gerguri A, Bejiqi R, Ratkoceri R, Maloku A, et al. Lafora disease: a case report. J Med Case Rep. 2022;16(1):360.
Gjerulfsen CE, Nikanorova M, Olofsson K, Johannessen Landmark C, Rubboli G, Møller RS. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study. Epilepsia Open. 2024;9(5):1891-900.
Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2021;1(1):Cd003032.
Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, et al. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020;91(10):1067-75.
Liu YH, Liang JS, Chang MY, Hung PL, Tsai MH, Chou IJ, et al. Dravet-like syndrome with PCDH19 mutations in Taiwan - A multicenter study. Pediatr Neonatol. 2025;66(3):230-4.
Devi N, Madaan P, Asrar MM, Sahu JK, Bansal D. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison. Seizure. 2021;91:316-24.
Kobayashi Y, Tohyama J, Takahashi Y, Goto T, Haginoya K, Inoue T, et al. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants. Brain Dev. 2021;43(4):505-14.
Borowicz-Reutt K, Czernia J, Krawczyk M. CBD in the Treatment of Epilepsy. Molecules. 2024;29(9).
Wong K, Junaid M, Alexander S, Olson HE, Pestana-Knight EM, Rajaraman RR, et al. Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database. CNS Drugs. 2024;38(9):719-32.
Huang X, Zhang Y, Lin Q, Huang K, Li Y, Liu P, et al. Association of valproate use and hippocampal atrophy in idiopathic generalized epilepsy. Neuroimage Clin. 2025;45:103744.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Hafsa Hameed Thakur , Haris Bin Umer , Muhammad Bilal Anwar , Shazma Khan , Amna Noor , Shanza Akbar (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
